Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 10,401–10,500 of 15,747
Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination
Sasajima, H., Zako, M., Maeda, R., & Ueta, Y. (2022) · Case Reports in Ophthalmology · doi:10.1159/000525151 · Cited by 4
Curtis, N. C., Shin, S., Hederman, A. P., Connor, R. I., Wieland‐Alter, W., Ionov, S., Boylston, J. A., Rose, J., Sakharkar, M., Dorman, D. B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.08.556349 · Cited by 4
“The majority of approved vaccines is based on prefusion-stabilized S, including BNT162b2 (Pfizer-BioNTech) (6), mRNA-1273 (Moderna) (7), and Ad26.”
Crosslinking of lipid nanoparticles enhances the delivery efficiency and efficacy of mRNA vaccines
Liu, X., Zhu, Y., Wei, C. Y., Lin, J., Yu, D., Kong, J., Shao, F., Ma, J., Xu, T., Lu, X., et al. (2026) · Nature Chemical Engineering · doi:10.1038/s44286-026-00356-5 · Cited by 6
“Following mRNA LNP assembly, the pH is adjusted to 7 to initiate crosslinking, forming crosslinked LNPs (cLNPs).”
Efficacy and safety of four COVID-19 vaccines in preventing SARS-CoV-2 infection: A rapid review
Morón-Duarte, L. S., Acevedo, K. R. C., Gutiérrez, M. P., Siegler, I. H. D. L. H., & Yomayusa, N. (2022) · Biomédica · doi:10.7705/biomedica.6254 · Cited by 5
“SD: Standard deviation Study Polack, 2020 [24] Baden, 2020 [25] Voysey, 2020 [26] [27] Logunov, 2021 [28]”
Evaluation of a Lateral Flow Immunoassay COVIDTECH® SARS-CoV-2 IgM/IgG Antibody Rapid Test
Exinger, J., Hartard, C., Lafferrière, F., Fenninger, C., Charbonnière, L. J., & Jeulin, H. (2021) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2021.273 · Cited by 3
Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19
Hashem, M., & El‐Kassas, M. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i10.2140 · Cited by 3
Impfungen als Schlüssel der Pandemiebewältigung: Erkenntnisse aus der COVID-19-Pandemie
Le, N. H., Hillus, D., Tober‐Lau, P., & Sander, L. E. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2124-2366 · Cited by 3
“Entwicklung, Zulassung und Rollout hochwirksamer COVID-19-Impfstoffe COVID-19-Impfstoffe gelangen somit in unter einem Zehntel der üblichen Zeit – ohne relevante Einschränkungen beim Umfang oder der Qualität der Prü-fung.”
BackgroundJames, S. L., Bourgognon, M., Vieira, P. P., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103079 · Cited by 3
Deng, H., Li, Y., Wang, G., & Li, R. (2025) · Biology · doi:10.3390/biology14010067 · Cited by 4
COVID-19 vaccine hesitancy in KwaZulu-Natal, South Africa: A survey of unvaccinated adults
Gengiah, T. N., Naidoo, D. C., Maduma, N., et al. (2024) · Health SA Gesondheid · doi:10.4102/hsag.v29i0.2468 · Cited by 3
“The benefits of vaccination against COVID-19 include protection from severe disease, reduced mortality rates, and reduced need for hospitalisation while offering protection to others by reducing the onward transmission of COVID-19 (Polack et al. 2020; Sadoff et al. 2021).”
BackgroundEffectiveness of COVID-19 Vaccines: Eight Months Post Single Dose Vaccination
(2021) · doi:10.1101/2021.09.18.21263262 · Cited by 3
“The efficacy of BNT162b2 vaccine in preventing symptomatic COVID-19 infection was 52% (95% CI: 30–86%) after one dose and 95% (95% CI: 90–98%) after two doses in clinical trial settings (8).”
BackgroundRoberts, C. H., Brindle, H. E., Rogers, N. T., et al. (2021) · medRxiv · doi:10.1101/2021.07.13.21260425 · Cited by 3
Antibody Titers 3-Months Post-Vaccination with the Pfizer/Biontech Vaccine in GreecePreprint
Κοντοπούλου, Κ., Nakas, C. T., Ntenti, C., Katsioulis, C., Goulas, A., & Papazisis, G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3899094 · Cited by 4
Fernández‐Lázaro, D., Garrosa, M., Sánchez-Serrano, N., Garrosa, E., Jiménez-Callejo, E., Yanguas, M. D. P., Mielgo‐Ayuso, J., & Seco‐Calvo, J. (2022) · Vaccines · doi:10.3390/vaccines10081170 · Cited by 5
“3 mL dose contains 30 μg of purified mRNA in lipid nanoparticles [21].”
MethodBecker, J. E., Shebl, F. M., Losina, E., Wilson, A. C., Levison, J. H., Donelan, K., Fung, V., Trieu, H. D., Panella, C., Qian, Y., et al. (2024) · Implementation Science Communications · doi:10.1186/s43058-024-00593-w · Cited by 4
“At the same time, the development and approval of vaccinations in the United States during the planning stages of the implementation trial required a course shift and rapid incorporation of vaccination into the model that was not present as an option in the early planning stages of the study [48].”
BackgroundCOVID-19 in Relation to Polypharmacy and Immunization (2020–2024)
Puigdellívol‐Sánchez, A., Juanes-González, M., Calderón-Valdiviezo, A., Valls-Foix, R., González-Salvador, M., Lozano-Paz, C., & Vidal‐Alaball, J. (2024) · Viruses · doi:10.3390/v16101533 · Cited by 3
“…aged over 70 years, the vaccination included mRNA vaccines: 3 doses of the BNT162b2 mRNA COVID-19 vaccine (Comirnaty from P fi zer-BioNTech) [20] or mRNA-1273 from Moderna [21] (for selected immunosuppressed patients) during 2021 (2 doses in the spring of 2021 and 1 booster dose in the…”
BackgroundPavlidis, G., Giannoulis, V., Pirounaki, M., Lampropoulos, I. C., Siafi, E. P., Nitsa, A., Pavlou, E. G., Xanthaki, A., Perlepe, G., Fortis, S. P., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060910 · Cited by 4
Warner, B. M., Chan, M., Tailor, N., Vendramelli, R., Audet, J., Meilleur, C. E., Truong, T., Garnett, L., Willman, M., Soule, G., et al. (2024) · Vaccines · doi:10.3390/vaccines12040404 · Cited by 7
“Several vaccine candidates, specifically targeting the viral spike protein, were developed with a massive effort to complete phase III efficacy trials in record time [21–25].”
Choudhary, A. K., Lerman, M. J., Calianese, D. C., Khan, S., Hunt, J. M., Nikaein, A., Rosenberg, A. Z., Silverberg, J. I., Zyskind, I., Honnen, W. J., et al. (2022) · medRxiv · doi:10.1101/2022.02.10.22270607 · Cited by 4
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections
Petcherski, A., Tingley, B. M., Martin, A., Adams, S. C., Brownstein, A. J., Steinberg, R. A., Shabane, B., Ngo, J., Osto, C. A., Garcia, G., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202403182 · Cited by 8
“To combat this crisis, Pfizer and Moderna, among others, developed highly efficacious vaccines (BNT162b2 and mRNA-1273, respectively) at unprecedented speeds which display >94% efficacy in preventing COVID-19 illness, including severe disease (Baden et al , 2021; Polack et al , 2020).”
Calimeri, S., Giudice, D. L., Buda, A., Laganà, A., Facciolà, A., Pietro, A. D., & Visalli, G. (2023) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.4.2742 · Cited by 4
Interaction Analysis by Fragment Molecular Orbital Method for Drug Discovery Research
Kawashita, N. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00448 · Cited by 3
Gordon‐Lipkin, E. M., Marcum, C. S., Kruk, S., Thompson, E., Kelly, S., Kalish, H. R., Bellusci, L., Khurana, S., Sadtler, K., & McGuire, P. J. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1100 · Cited by 2
Ishii, H., Terahara, K., Nomura, T., Okazaki, M., Yamamoto, H., Shu, T., Sakawaki, H., Miura, T., Watkins, D. I., & Matano, T. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.023 · Cited by 4
The Evolving Maternal Vaccine Platform
Adams, R. M., & Gonik, B. (2024) · Reproductive Medicine · doi:10.3390/reprodmed5030014 · Cited by 4
“Initial vaccine safety data on pregnant women who elected to receive the COVID-19 vaccine or were inadvertently immunized were collected to determine infection rate, maternal antibody response, antibody transfer, local adverse events, and systemic adverse events [24].”
BackgroundShelkovnikova, T. A., Сергеевна, М. А., Игоревна, Р. Н., Витальевна, М. О., Харисович, В. В., Ussov, W. Y., & Anfinogenova, Y. (2023) · Journal of Imaging · doi:10.3390/jimaging9060108 · Cited by 3
“although the availability of effective vaccines resulted in a decrease in the burden of acute coronavirus infection [15,16].”
BackgroundColaneri, M., Asperges, E., Calia, M., Sacchi, P., Rettani, M., Cutti, S., Albi, G., & Bruno, R. (2022) · Vaccines · doi:10.3390/vaccines10091540 · Cited by 4
Zhang, F., Li, C., Wu, Y., Chuan, H., Song, S., Xie, Y., Zhu, Q., Chen, Q., Tong, F., Zhang, R., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136536 · Cited by 5
“Given the demonstrated safety and adaptability of mRNA platforms, as seen in COVID-19 vaccines, this approach holds potential for tackling the epidemiological and drug resistance challenges of M. pneumoniae [26–29].”
Li, H., Sahu, K. K., Kumar, S. A., Nordblad, B., Sayegh, N., Tripathi, N., Thomas, V. M., Gupta, S. V., Maughan, B. L., Agarwal, N., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10583 · Cited by 3
Salbaş, E., Öcek, Ö., Öcek, L., et al. (2021) · Ege Tıp Bilimleri Dergisi · doi:10.33713/egetbd.969419 · Cited by 3
Panchawagh, S., Doskaliuk, B., Kuwana, M., et al. (2023) · Rheumatology International · doi:10.1007/s00296-023-05441-z · Cited by 3
An Updated and Focused Review on Heterocyclic Inhibitors for SARSCoV and SARS-CoV-2 3CLpro
Alam, O., Manaithiya, A., Mittal, S., Naim, M. J., Imran, M., Alshrari, A. S., Sheikh, A. A., & Khan, I. A. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220511125102 · Cited by 4
Islam, M. A., Nahar, M. T., Rahman, A., Monjur-Al-Hossain, A. S. M., Jui, U. J., Tabassum, T., Barna, S. D., Tahmida, S., Mishu, A. A., Parvin, S., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1361374 · Cited by 6
Are, E. B., Song, Y., Stockdale, J. E., Tupper, P. F., & Colijn, C. (2021) · medRxiv · doi:10.1101/2021.12.18.21268002 · Cited by 3
“We take our baseline values from studies on the Pfizer vaccine, giving vd = 95% protective against symptomatic infection [20] and ve = 80% protective against infection [21], implying a value of vp = 75%.”
MethodYoung, J. H. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.08.003 · Cited by 3
“The development of two mRNA vaccines [2] and an adenovirus vaccine [3] represents SARS-CoV-2 technology that has been studied in healthy adults.”
BackgroundThe Psychological Gains from COVID-19 Vaccination: Who Benefits the Most?
Bagues, M. F., & Dimitrova, V. (2021) · Journal of Public Economics · doi:10.1016/j.jpubeco.2025.105304 · Cited by 8
Berec, L., Levínský, R., Weiner, J., Šmíd, M., Neruda, R., Vidnerová, P., & Suchopárová, G. (2022) · Scientific Reports · doi:10.1038/s41598-022-11250-4 · Cited by 3
Improving the Efficacy of Cancer mRNA Vaccines
Kirtane, A. R., & Traverso, G. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000764 · Cited by 3
“83,84 Several lipids have been used as immune-activating agents.”
Cai, S., Chang, C., Zhang, X., & Qiao, W. (2023) · Medicine · doi:10.1097/md.0000000000034805 · Cited by 4
“3% for all other races after 2 doses of BNT162b2 vaccine.[25]”
BackgroundMøiniche, M. V. B., Johansen, K. H., Parrón‐Ballesteros, J., Corneliussen, J. K., Eriksen, H. H., Voss, L. F., Rosado, B. M., Furland, U. F., Kringelum, J. V., Hadrup, S. R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69134-4 · Cited by 6
Comments on Kämmerer, et al. (2023) regarding RT-PCR Testing
Franchi, F., & Tomšič, J. (2023) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v3i1.81 · Cited by 3
Ivanusic, D., Maier, J. M., Icli, S., Falcone, V., Bernauer, H. S., & Bannert, N. (2024) · iScience · doi:10.1016/j.isci.2024.109123 · Cited by 3
mRNA vaccines do not stop with COVID-19
Zhou, J., Zhang, Y., Mo, K., Newbert, H., & Song, X. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01514-3 · Cited by 3
Zhen, Z., Darji, M., Lin, X., Bogner, R. H., & Lü, X. (2026) · AAPS Open · doi:10.1186/s41120-026-00146-6 · Cited by 3
Progress and Prospects for Non‐Viral Gene Therapy
Tiwari, S. (2023) · doi:10.1002/9781394175635.ch5 · Cited by 3
Vaccination strategies for minimizing loss of life in Covid-19 in a Europe lacking vaccinesPreprint
Hunziker, P. (2021) · medRxiv · doi:10.1101/2021.01.29.21250747 · Cited by 3
Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines
Pesce, M., Feikin, D. R., Higdon, M. M., O’Brien, K. L., Patel, M. K., Rearte, A., Vizzotti, C., Wilder‐Smith, A., & Parker, E. P. K. (2025) · Nature Communications · doi:10.1038/s41467-025-63950-w · Cited by 8
Post-COVID mRNA vaccine myocarditis in children: report of two cases
Shamekh, A., Powell, C., Ashabani, A., & Abdelgadir, I. S. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-253383 · Cited by 3
Worth a shot? The political economy of government responsiveness in times of crisis
Gutiérrez, E., Meriläinen, J., & de León, M. P. (2024) · World Development · doi:10.1016/j.worlddev.2024.106762 · Cited by 5
COVID-19 vaccine-induced liver injury
Shroff, H. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001012 · Cited by 3
Asadi, M., Naderi, D., & Jahanshahi, F. (2023) · SAGE Open Medical Case Reports · doi:10.1177/2050313x231191237 · Cited by 3
Immunological heterogeneity informs estimation of the durability of vaccine protection
de Cellès, M. D., Wong, A., Guevara, L. A. B., & Rohani, P. (2022) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0070 · Cited by 3
“Other vaccine attributes were assumed known and were fixed based on the results of clinical trials and early epidemiological studies of mRNA vaccines: vaccine effectiveness of 95% against clinical infections[41,42] and of 90% against subclinical infections[43].”
BackgroundKasuga, I., Gamo, S., Yokoe, Y., SUGIYAMA, T., TOKURA, M., NOGUCHI, M., Okayama, M., TAKEDA, Y., SATO, T. A., Mori, M., et al. (2022) · Health Evaluation and Promotion · doi:10.7143/jhep.49.462 · Cited by 3
COVID-19-Related Predictors of Fear and Attitude to Vaccination Displayed by Polish Students
Bartosiewicz, A., Łuszczki, E., Bartosiewicz, A., Dereń, K., Oleksy, Ł., & Stolarczyk, A. (2022) · Vaccines · doi:10.3390/vaccines10091524 · Cited by 3
Epidemiologische Ansätze zur Klärung wichtiger Forschungsfragen zu COVID-19 – eine Übersicht
Zeeb, H., Ahrens, W., Haug, U., Grabenhenrich, L., & Pigeot, I. (2021) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-021-03378-x · Cited by 3
Booster effect of a third mRNA ‐based COVID ‐19 vaccine dose in patients with myeloid malignancies
Mori, A., Onozawa, M., Kobayashi, M., Tsukamoto, S., Senjo, H., Ishio, T., Yokoyama, E., Kanaya, M., Izumiyama, K., Saito, M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6314 · Cited by 2
Iatropoulos, S., Dandrieux, P., Navarro, L., Blanco, D., & Édouard, P. (2025) · Sports Medicine · doi:10.1007/s40279-025-02298-z · Cited by 4
An in‐depth analysis of COVID‐19 treatment: Present situation and prospects
Islam, M. A., Pathak, K., Saikia, R., Pramanik, P., Das, A., Talukdar, P., Shakya, A., Ghosh, S. K., Singh, U. P., & Bhat, H. R. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400307 · Cited by 3
Layton, J. B., Lloyd, P. C., Peetluk, L. S., Jiao, Y., Djibo, D. A., Gruber, J. F., Deng, J., Bui, C. L., Lo, A., Ogilvie, R. P., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320434 · Cited by 4
Hasan, I., Alharthi, F. A., Bishoyi, A. K., Menon, S. V., Thakur, R., Supriya, S., Ray, S., & Joshi, K. K. (2025) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2025.03.017 · Cited by 3
Unpacking the Drop in COVID-19 Case Fatality Rates: A Study of National and Florida Line-Level Data
Cheng, C., Zhou, H. H., Weiss, J. C., & Lipton, Z. C. (2020) · PubMed · doi:10.48550/arxiv.2012.04825 · Cited by 5
Neto, F. L., Mercadé‐Besora, N., Raventós, B., Pérez‐Crespo, L., de Castro, G., Ranzani, O., & Duarte‐Salles, T. (2024) · Nature Communications · doi:10.1038/s41467-024-49285-y · Cited by 6
A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues
Wu, B., Liu, Y., Zhang, X., Luo, D., Wang, X., Qiao, C., & Liu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420216 · Cited by 7
Konnova, A., Winter, F. D., Gupta, A., Verbruggen, L., Hotterbeekx, A., Berkell, M., Teuwen, L.-A. M. N., Vanhoutte, G., Peeters, B., Raats, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1062136 · Cited by 3
“The BNT162b2 mRNA COVID-19 vaccine elicits a range of immunological responses, especially a strong anti-SARS-CoV-2 IgG response in healthy individuals, although it starts waning after approximately 6 months [1-3].”
BackgroundZimmermann, L., & Erbar, S. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_5 · Cited by 4
Receptor-Binding-Domain-Specific B Cell Responses Induced by mRNA Immunization against SARS-CoV-2
Geropeppa, M., Papadatou, I., Sarantis, P., Tzanoudaki, M., Ntanasis‐Stathopoulos, I., Bagratuni, T., Terpos, E., & Spoulou, V. I. (2023) · Vaccines · doi:10.3390/vaccines11071148 · Cited by 3
“Prior to enrollment, previous COVID-19 infection was excluded using the immunoassay Elecsys® Anti-SARS-CoV-2 (Roche Diagnostics, Rotkreuz, Switzerland) for the semiquantitative detection of total antibodies (IgA, IgM, and IgG) against the SARS-CoV-2 nucleocapsid protein, following the manufacturer’s instructions.”
BackgroundErythema nodosum at COVID ‐19 vaccine injection site
Matsuoka, A., Higashi, Y., & Kanekura, T. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16613 · Cited by 3
The course of patients with hairy cell leukemia during the omicron surge of the Covid‐19 pandemic
Tadmor, T., Melamed, G., Patalon, T., Alapi, H., & Rokach, L. (2023) · Hematological Oncology · doi:10.1002/hon.3203 · Cited by 3
Cutaneous reactions due to Pfizer's BNT162b2 mRNA and Moderna's mRNA‐1273 vaccines
Oulee, A., Salem, S. Z., Yahia, R., Yang, K., Garcia, D., Holmes, A., & Furukawa, B. J. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17925 · Cited by 3
İremli, B. G., Şendur, S. N., & Ünlütürk, U. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab823 · Cited by 3
Kim, C. Y., McNeill, E. N., Young, C., King, F., Clague, M., Caldwell, M., Boruah, A. P., Zucker, J. E., & Thakur, K. T. (2023) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200166 · Cited by 3
Mapelli, M., Amelotti, N., Andreini, D., Baggiano, A., Campodonico, J., Moltrasio, M., Majocchi, B., Mantegazza, V., Vignati, C., Ribatti, V., et al. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartj/suac018 · Cited by 3
Can the immune system be targeted to treat COVID-19?
Abdelhafeez, S., & Doherty, D. G. (2021) · European Respiratory Society eBooks · doi:10.1183/2312508x.10024120 · Cited by 3
Unninayar, D., Falcone, E. L., Chapdelaine, H., Vinh, D. C., Top, K. A., Dérfalvi, B., Issekutz, T. B., Decaluwe, H., Pham‐Huy, A., Upton, J. E. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1501908 · Cited by 3
Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
Agrati, C., Castilletti, C., Sacchi, A., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16565 · Cited by 3
Jurgens, G., & Lackner, K. S. (2021) · medRxiv · doi:10.1101/2021.02.28.21252638 · Cited by 4
Silva, V. M., Capela, T. L., Freitas, M., Gonçalves, T. C., Carvalho, P. B., de Castro, F. D., Moreira, M. J., & Cotter, J. B. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac187 · Cited by 5
Brazete, C. S., Pinto, M. S. D. S., Sá, L., Aguiar, A., Alves, F., & Duarte, R. (2022) · Vaccines · doi:10.3390/vaccines10050822 · Cited by 4
Chen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L. M., Tan, T. K., Rijal, P., Chen, C., Cheng, S., Lee, W.-H., Chou, Y., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012246 · Cited by 3
Adverse reactions of COVID-19 vaccination: where do they come from?
Pruc, M., Gąsecka, A., Szarpak, Ł., et al. (2021) · Disaster and Emergency Medicine Journal · doi:10.5603/demj.a2021.0004 · Cited by 3
Rasheed, N., Khan, J. A., Yusuf, A., Khan, A. S., Mustajab, A., Majeed, R., & Hashmi, A. A. (2024) · Cureus · doi:10.7759/cureus.51583 · Cited by 2
“The AstraZeneca vaccine received authorization for use in people aged 18 and above, and it demonstrated 66% effectiveness against COVID-19 [7].”
BackgroundGobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2021) · medRxiv · doi:10.1101/2021.08.04.21261507 · Cited by 3
Muhsen, K., Waight, P. A., Kirsebom, F. C. M., Andrews, N. J., Letley, L. H., Gower, C., Skarnes, C., Quinot, C., Lunt, R., Bernal, J. L., et al. (2024) · Vaccines · doi:10.3390/vaccines12020113 · Cited by 3
“This approach captures changes in immunity over time since vaccination, both the development and waning immunity [9,45–47].”
BackgroundChen, X., Zhang, H., Liu, D., Ma, J., Jin, L., Ma, Y., Li, J., Song, G., & Wang, J. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00117j · Cited by 4
COVID-19 Pandemic: the story is not over yet
Piarroux, R., Gaudart, J., & Rebaudet, S. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100802 · Cited by 3
Sanmarchi, F., Gibertoni, D., Golinelli, D., Gori, D., Fantini, M. P., & Scheier, L. M. (2022) · Scandinavian Journal of Public Health · doi:10.1177/14034948221134187 · Cited by 10
“[4] Polack FP, Thomas SJ, Kitchin N, et al.”
BackgroundSeminar Lessons: Infectious Diseases Associated with and Causing Disaster
Hattori, T., Yasutan, H. C., Koga, S., Yanagihara, Y., & Tanaka, I. (2022) · Reports — Medical Cases Images and Videos · doi:10.3390/reports5010007 · Cited by 4
“Furthermore, immunogenicity and BNT162b2, a lipid nanoparticle-formulated, nucleoside-modified RNA (modRNA) encoding the SARS-CoV-2 full-length spike, modified by two proline mutations that lock it in the prefusion conformation, were proven to be safe and effective [44].”
BackgroundIvanov, N., Krastev, B. M., Miteva, D., Batselova, H., Alexandrova, R., & Velikova, T. V. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i9.343 · Cited by 3
Kruglov, A., Bondareva, M. A., Gogoleva, V. S., Semin, I. K., Astrakhantseva, I. V., Zvartsev, R. V., Lunin, A. S., Apolokhov, V. D., Shustova, E. Y., Volok, V. P., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202350664 · Cited by 4
“Numerous vaccines against the initial Wuhan strain of SARS-CoV-2 were developed, including vector-based vaccines [28–31], mRNA-based vaccines [32, 33], protein-based vaccines [34–37], as well as inactivated whole virion SARS-CoV-2 vaccines [24, 38-41].”
BackgroundProgramming systemic and mucosal immunity through co-adjuvant-based prime-boost vaccination
Uematsu, S. (2026) · Current Opinion in Virology · doi:10.1016/j.coviro.2026.101525 · Cited by 3
Filippo, M. D., Ferraro, D., Ragonese, P., Prosperini, L., Maniscalco, G. T., Gallo, A., Cavalla, P., Lorefice, L., Nociti, V., Sabatino, E. D., et al. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12034-0 · Cited by 3
Ishii, H., Jounai, K., Tsuji, R. F., Ohshio, K., Kaneda, D., Okazaki, M., Harada, S., Fujiwara, D., & Matano, T. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.046 · Cited by 4
Mehta, D., Kelkar, R., Patel, N., Trivedi, P., Dawoodi, S. L., Patel, D., Solanki, D., Hussain, A., Nagaraj, S., Khayat, A., et al. (2023) · Cureus · doi:10.7759/cureus.47028 · Cited by 5
“While vaccines are showing great promise for curbing the spread of this virus [20,21], SARS-CoV-2 may mutate to the point of vaccine resistance.”
BackgroundDeterminants of the willingness to get the third COVID-19 vaccine dose among health care workers
Paris, C., Saade, A., Tadié, É., Van, R. N., Turmel, V., Garlantézec, R., & Tattevin, P. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.04.007 · Cited by 3
“[2] Polack FP, Thomas SJ, Kitchin N, et al.”
Zhang, B., Upadhyay, R., Hao, Y., Samanovic, M. I., Herati, R. S., Blair, J., Axelrad, J. E., Mulligan, M. J., Littman, D. R., & Satija, R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.24.525203 · Cited by 3
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.